A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants With Recent Onset Chronic Cough
A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants With Recent Onset Chronic Cough
The purpose of this study is to evaluate the efficacy and safety of gefapixant in participants with recent onset chronic cough (duration >8 weeks after onset of cough symptoms) for <12 months and a diagnosis of refractory or unexplained chronic cough. The primary hypothesis is that gefapixant is superior to placebo in improving cough-related quality of life measured as change from baseline in the Leicester Cough Questionnaire (LCQ) total score at Week 12.
Inclusion Criteria:
Exclusion Criteria:
Williamsburg, Virginia 23188, United States
Medellín, Antioquia 050036, Colombia
Marburg, Hesse 35037, Germany
Neu-Isenburg, Hesse 63263, Germany
Guatemala City, 01010, Guatemala
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
Krakow, Lesser Poland Voivodeship 30-033, Poland
Zawadzkie, Opole Voivodeship 47-120, Poland
Belgorod, Belgorod Oblast 308007, Russia
Kemerovo, Kemerovo Oblast 650000, Russia
Moscow, Moscow 115419, Russia
Saint Petersburg, Sankt-Peterburg 194354, Russia
Saint Petersburg, Sankt-Peterburg 195271, Russia
Saratov, Saratov Oblast 410012, Russia
Ulyanovsk, Ulyanovsk Oblast 432063, Russia
Yaroslavl, Yaroslavl Oblast 150040, Russia
Songpagu, Seoul 05505, South Korea
Santiago de Compostela, La Coruna 15706, Spain
Madrid, Madrid, Comunidad de 28007, Spain
Kherson, Kherson Oblast 73000, Ukraine
Kyiv, Kyivska Oblast 03038, Ukraine
Kyiv, Kyivska Oblast 03038, Ukraine
Kyiv, Kyivska Oblast 03057, Ukraine
Vinnytsia, Vinnytsia Oblast 21001, Ukraine
Vinnytsia, Vinnytsia Oblast 21018, Ukraine
Zaporizhzhya, Zaporizhzhia Oblast 69096, Ukraine